News

Articles

This year's CPHI award winners emphasize achievements in pharma excellence.

CPHI Announces Excellence in Pharma Awards (CPHI Milan 2024)

Feliza Mirasol is the science editor for 

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

Lilly Plans to Grow its Biologics Manufacturing Footprint in Ireland with $1.8 Billion Expansion

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline

Novo Nordisk plans to invest $4.1 billion in a second fill/finish manufacturing facility in Clayton, N.C., boosting its current 2024 investments into production to $6.8 billion.

Novo Nordisk Targets $4.1 Billion Expansion of US Manufacturing Capacity 

Under an agreement, Johnson & Johnson will acquire Numab Therapeutics’ wholly owned subsidiary to gain global rights to NM26, a bispecific antibody targeting atopic dermatitis. 

Johnson & Johnson Pursues Global Rights to Numab Therapeutics’ AD-Targeting Bispecific Antibody in $1.25 Billion Acquisition

Biogen’s acquisition of HI-Bio includes lead investigational mAb, felzartamab, under development for treating a range of immune-mediated diseases. 

Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio 

The Mirus Bio acquisition will boost Merck KGaA’s viral vector manufacturing services. 

Merck KGaA Set to Acquire Mirus Bio in $600 Million Deal

Mariana’s portfolio of radioligand therapies will strengthen Novartis’ radioligand therapy pipeline.

Top News